Vedanta Biosciences
Cambridge, US · Delaware corporation · 7 known investors
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection. Its oral therapies target gut dysbiosis-driven conditions.
Founders & leadership
BO
Bernat OlleFounder
DC
Daniel CoutoExecutive
MM
Mark MullikinExecutive
JS
Jeffrey SilberExecutive
CV
Christopher ViehbacherNamed on SEC filing
Board
JL
John LaMattinaBoard director
CS
Charles SherwoodBoard director
MH
NT
Neil TiwariBoard director
CL
Curt LaBelleBoard director
BS
Bennett ShapiroBoard director
TI
Troy IgnelziBoard director
Investors · 7
Funding
SEC filings, press & company announcements$300.3M disclosed across 5 rounds · 2018–2026
- $60MraisedAug 2026 · 3 sourcesSource ↗
▶$118.5MraisedAug 2024 · 25 investors · BiotechnologyRule 506(b)
▶$118.5MraisedAug 2024 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John LaMattinaDirector
- Charles SherwoodDirector
- Susan DillonDirector
- Martin HeideckerDirector
- Neil TiwariDirector
- Curt LaBelleDirector
- Daniel CoutoExecutive Officer
- Bernat OlleExecutive Officer, Director
- Mark MullikinExecutive Officer
- Bennett ShapiroDirector
- Troy IgnelziDirector
- Jeffrey SilberExecutive Officer
- Offering amount
- $118.5M
- Amount sold
- $118.5M
- Sales commissions
- $400K
- Placement agents
- FJS Consultants Limited
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$68.4MraisedAug 2021 · 18 investors · BiotechnologyRule 506(b)
▶$68.4MraisedAug 2021 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher ViehbacherDirector
- Bernat OlleExecutive Officer, Director
- Susan DillonDirector
- Troy IgnelziDirector
- John L LaMattinaDirector
- Daniel CoutoExecutive Officer
- Bharatt ChowriraDirector
- Mark MullikinExecutive Officer
- Bennett M ShapiroDirector
- Jeffrey SilberExecutive Officer
- Offering amount
- $75M
- Amount sold
- $68.4M
- Sales commissions
- $400K
- Placement agents
- FJS Consultants Limited
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedSep 2019 · 4 investors · Other Health CareRule 506(b)
▶$8MraisedSep 2019 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Susan DillonDirector
- Bharatt ChowriraDirector
- Bennett M. ShapiroDirector
- John L. LaMattinaDirector
- Christopher ViehbacherDirector
- Bernat OlleExecutive Officer, Director
- Offering amount
- $16.6M
- Amount sold
- $8M
- Sales commissions
- $160K
- Placement agents
- China eCapital Partners, LLC
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45.4MraisedMay 2019 · 13 investors · Other Health CareRule 506(b)
▶$45.4MraisedMay 2019 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bernat OlleExecutive Officer, Director
- Bharatt ChowriraDirector
- Bennett M. ShapiroDirector
- John L. LaMattinaDirector
- Christopher ViehbacherDirector
- Susan DillonDirector
- Offering amount
- $50M
- Amount sold
- $45.4M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Vedanta Biosciences went on to found or lead other companies.
Competitors · 4
by search overlapEnanta Pharmaceuticals23 shared keywordsEnanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).
VintaBio22 shared keywordsVintaBio provides viral vector manufacturing for clinical and commercial gene therapies, using a single-stream process (VintaProcess) to produce high-yield, high-purity vectors. It offers end-to-end services from discovery through final delivery for cell and gene therapy developers.
Vanda16 shared keywordsVanda Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapies, with a clinical development pipeline of drug candidates. It provides information for investors, career seekers, and the public on its innovations and their development stages.
Proxima15 shared keywordsProxima is a biotech company developing proximity therapeutics through a drug discovery engine and a structural proteomics data platform.
Companies competing with Vedanta Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Vedanta Biosciences do?
- Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection. Its oral therapies target gut dysbiosis-driven conditions.
- Who founded Vedanta Biosciences?
- Vedanta Biosciences was founded by Bernat Olle.
- Who are Vedanta Biosciences's investors?
- Vedanta Biosciences's investors include AMR Action Fund, K2 HealthVentures, Salica Investments, Seventure Partners, BNP Paribas, BNP Paribas Asset Management Europe, Tullis.
- How much funding has Vedanta Biosciences raised?
- Vedanta Biosciences has disclosed $300.3M raised across 5 rounds.
- Where is Vedanta Biosciences headquartered?
- Vedanta Biosciences is headquartered in Cambridge, US.